...
首页> 外文期刊>OncoTargets and therapy >Knockdown of KLK11 reverses oxaliplatin resistance by inhibiting proliferation and activating apoptosis via suppressing the PI3K/AKT signal pathway in colorectal cancer cell
【24h】

Knockdown of KLK11 reverses oxaliplatin resistance by inhibiting proliferation and activating apoptosis via suppressing the PI3K/AKT signal pathway in colorectal cancer cell

机译:敲低KLK11通过抑制结直肠癌细胞的增殖和通过抑制PI3K / AKT信号通路激活凋亡来逆转奥沙利铂耐药性

获取原文
           

摘要

Introduction: Kallikrein 11 (KLK11) plays a crucial role in drug-resistance to oxaliplatin (L-OHP) in the treatment of metastatic colorectal cancer (mCRC). The study aimed to investigate the role of KLK11 in chemoresistance, and to clarify the mechanism underlying reverse of L-OHP resistance by knockdown of KLK11. Materials and Methods: Resistance to oxaliplatin was induced in HCT-8 (HCT-8/L-OHP) colorectal adenocarcinoma cell lines by exposing cells to increasing concentrations of L-OHP. MTT, RT-qPCR, and Western blot were used to evaluate the resistance to L-OHP. We then knocked down KLK11 in HCT-8/L-OHP cells to explore the mechanism through which KLK11 reverses L-OHP resistance. The mRNA and protein expression of KLK11 in tissues from mCRC patients were detected by RT-qPCR and immunohistochemistry. Results: The drug resistance index (RI) of HCT-8/L-OHP cell line to L-OHP, 5-Fluorouracil (5-FU), Irinotecan (CPT-11), Vincristine (VCR) and Cis-diamminedichloroplatinum (CDDP) were 10, 5.35, 3.23, 1.28, and 6.64, respectively. Increased expression of multi-drug resistant genes ABCC1 , ABCB1 , GSTP1 and ERCC1 were detected in HCT-8/L-OHP cell line. Moreover, the activated PI3K/AKT pathway was related to L-OHP-resistance. Knockdown of KLK11 in HCT-8/L-OHP cell reversed L-OHP-resistance by inhibiting cell growth and activating apoptosis via suppressing the PI3K/AKT signaling pathway. Moreover, high expression of KLK11 in chemoresistant-patients was associated with lymph node metastases and histopathology. Conclusion: KLK11 was highly expressed in chemoresistant-patients and L-OHP-resistant cell lines. Moreover, L-OHP resistance was associated with activated PI3K/AKT signal pathway. Knockdown of KLK11 can reverse L-OHP resistance by blocking PI3K/AKT signaling pathway.
机译:简介:激肽释放酶11(KLK11)在对转移性结直肠癌(mCRC)的治疗中对奥沙利铂(L-OHP)的耐药性中起着至关重要的作用。该研究旨在调查KLK11在化学抗性中的作用,并阐明通过敲低KLK11逆转L-OHP耐药性的潜在机制。材料和方法:通过将细胞暴露于增加的L-OHP浓度,在HCT-8(HCT-8 / L-OHP)大肠腺癌细胞系中诱导出对奥沙利铂的抗性。使用MTT,RT-qPCR和Western印迹评估对L-OHP的抗性。然后,我们敲低了HCT-8 / L-OHP细胞中的KLK11,以探索KLK11逆转L-OHP耐药性的机制。 RT-qPCR和免疫组化检测mCRC患者组织中KLK11的mRNA和蛋白表达。结果:HCT-8 / L-OHP细胞系对L-OHP,5-氟尿嘧啶(5-FU),伊立替康(CPT-11),长春新碱(VCR)和顺二氨二氯铂(CDDP)的耐药指数(RI) )分别为10、5.35、3.23、1.28和6.64。在HCT-8 / L-OHP细胞系中检测到多重耐药基因ABCC1,ABCB1,GSTP1和ERCC1的表达增加。此外,激活的PI3K / AKT途径与L-OHP抵抗有关。敲低HCT-8 / L-OHP细胞中的KLK11可以通过抑制细胞生长并通过抑制PI3K / AKT信号通路激活细胞凋亡来逆转L-OHP耐药性。此外,化学耐药患者中KLK11的高表达与淋巴结转移和组织病理学有关。结论:KLK11在耐化学药品的患者和对L-OHP耐药的细胞株中高表达。此外,L-OHP抵抗与激活的PI3K / AKT信号通路相关。敲低KLK11可以通过阻断PI3K / AKT信号通路来逆转L-OHP耐药性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号